Delcath Systems (DCTH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.07
- Estimate
- -$0.10
- Surprise
- +166.7%
- Revenue (period 2026-06-30)
- $29.1M
- Score at report (before → after)
- 7.1 → 7.0/10
Revenue source: xbrl.
How the report landed
Delcath Systems (DCTH) beat the -$0.10 estimate with adjusted EPS of $0.07 — a large 166.7% upside surprise. TrendMatrix's engine moved from Hold (7.1/10) to Buy (Wait) at 7.0/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates DCTH Hold at 6.6/10.
3 of the last 4 quarters beat the estimate; this quarter's +166.7% surprise compares with a +127.8% four-quarter average. Next scheduled report: 2027-02-25.
What supports the rating
- Strong earnings beat streak (3/4)
- Strong growth profile
What argues against it
- Concentration risk — Product: HEPZATO
- Concentration risk — Supplier: melphalan supplier
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.87
- Price target
- $24.88
- Stop
- $18.48
- Upside to target
- +25.2%
- Reward-to-risk
- 1.7:1
The stock trades at 128.4× trailing but 75.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
DCTH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $714.9M
- P/E (fwd)
- 75.4
- P/E (ttm)
- 128.4
- 52-week range
- $8.12–$22.51
- Off 52-week high
- 11.7%
- RSI (14)
- 72
- Volume vs avg
- 1.23×
- Score today
- 6.6/10